Discovering Systemic Mastocytosis in Practice: A Webinar Preview With Lauren M. Madigan, MD

Advances in Diagnosis and Disease Recognition

Systemic mastocytosis is a multisystem disease with a broad spectrum of symptoms, making timely diagnosis challenging. Patients may present with gastrointestinal complaints, cutaneous manifestations, allergy or anaphylaxis, neurocognitive symptoms, and bone involvement. “Because these symptoms span so many organ systems and mimic common conditions, such as irritable bowel syndrome, patients are often labeled with multiple diagnoses before anyone considers systemic mastocytosis,” Dr. Madigan explained.

Dermatology plays a pivotal role in diagnosis. The fixed skin lesions of mastocytosis are among the few highly specific features of the disease. In the webinar, Dr. Madigan will discuss how careful recognition of these cutaneous signs can provide a crucial clue, prompting appropriate workup and referral.

Addressing Morbidity and the Need for Early Diagnosis

Even in its indolent forms, SM can be associated with substantial morbidity. “Many of our patients suffer for years without an appropriate diagnosis and therefore miss out on meaningful therapies,” Dr. Madigan noted. Associations such as recurrent anaphylaxis and osteoporosis underscore the importance of early recognition and proactive management. By attributing symptoms correctly to mastocytosis, clinicians can intervene earlier, reduce life-threatening reactions, and improve patients’ quality of life.

The Critical Role of Multidisciplinary Care

Given its multisystem impact, SM is inherently multidisciplinary. In addition to dermatologists, Dr. Madigan emphasized the importance of hematologists/oncologists, allergists, gastroenterologists, and endocrinologists—particularly those managing mastocytosis-related bone disease. She will highlight how coordinated care can optimize evaluation, risk stratification, and long-term follow-up, and how oncology clinicians can collaborate with dermatology and allergy/immunology to streamline diagnosis and treatment.

What to Expect in the Webinar

Dr. Madigan is eager to share both practical diagnostic strategies and the latest data on emerging therapies. Historically, care focused on antihistamines and other anti-mediator therapies, along with more toxic approaches for advanced disease. “The last five to ten years have been very exciting,” she shared, noting the advent of targeted therapies not only for advanced systemic mastocytosis but now also for patients with indolent disease who have a high burden of symptoms. The webinar will review currently FDA-approved options as well as agents in the pipeline and discuss how these therapies are reshaping expectations for symptom control and, in advanced subtypes, survival.

“I’m most excited to share that the treatment landscape has really changed for patients with SM,” Dr. Madigan concluded. “I think the misconception that there isn’t a lot to offer these patients, thankfully, is changing. I encourage people to join to learn more about the options that are now available to patients so we can really make a meaningful impact—both in quality of life and even in survival for patients with more advanced subtypes.”

Key Takeaways

• Systemic mastocytosis often presents with heterogeneous, nonspecific symptoms that delay diagnosis.
• Recognition of characteristic cutaneous lesions can be a critical diagnostic gateway.
• Even indolent SM carries significant morbidity, including anaphylaxis and osteoporosis, underscoring the need for early identification.
• Multidisciplinary care—spanning dermatology, hematology/oncology, allergy, gastroenterology, and endocrinology—is essential for optimal outcomes.
• A rapidly evolving therapeutic landscape, including new targeted agents, is expanding options for both indolent and advanced disease.

Be sure to register for the webinar on January 13th or February 2nd to gain practical insights on recognizing and managing systemic mastocytosis!